47 research outputs found

    Machine learning for radiation outcome modeling and prediction

    Full text link
    Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/155503/1/mp13570_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/155503/2/mp13570.pd

    Predicting successful clinical candidates for fiducial-free lung tumor tracking with a deep learning binary classification model

    Full text link
    Robotic radiosurgery allows for marker-less lung tumor tracking by detecting tumor density variations in 2D orthogonal X-ray images. The ability to detect and track a lung lesion depends on its size, density, and location, and has to be evaluated on a case-by-case basis. The current method for identifying which patient can be successfully treated with fiducial-free lung tumor tracking is a time-consuming process named Lung Optimized Treatment (LOT) simulation. The process involves CT acquisition, generation of a simulation plan, creation of the patient breathing model, and execution of the simulation plan on the treatment delivery platform. The aim of the study is to develop a tool to enable binary classification of trackable and non-trackable lung tumors for automatic selection of optimal tracking methods for patient undergoing robotic radiosurgery without having to perform the LOT simulation. We developed a deep learning classification model and tested 5 different network architectures to classify lung cancer lesions from enhanced digitally reconstructed radiographs (DRRs) generated from planning CTs. This study included 129 patients with single or multiple lesions, for a total of 144 lung lesions (n=115 trackable, n=29 untrackable). A total of 271 images were included in our analysis. We kept 80% of the images for training, 10% for validation, and the remaining 10% for testing. The binary classification accuracy reached 100% after training, both in the validation and the test set. Candidates for fiducial-free lung tumor tracking during robotic lung radiosurgery can be successfully identified by using a deep learning model classifying DRR images sourced from simulation CT scans.Comment: 19 pages, 7 figure

    Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.

    Get PDF
    A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients
    corecore